KRAS and non-small cell lung carcinoma: With excellent biocompatibility and high cellular uptake efficiency of NPNCD, the designed NPNCD with KRAS siRNA (NPNCDK) was further conjugated for KRAS-mutated nonsmall cell lung cancer therapy (NSCLC), illustrating excellent gene knockdown efficiency and anticancer effect in vitro.